The two largest pet insurance underwriters in North America have begun publishing actuarial modelling work exploring how widespread adoption of canine longevity drugs would change the lifetime claim profile of insured dogs — and, by extension, what it would do to premium structures, lifetime caps, and chronic-condition exclusions.

The early models suggest a counterintuitive result. Even though longevity drugs would extend the period over which a dog generates claims, the compression of end-of-life morbidity that the drugs are designed to produce reduces the total claim cost per insured year. The effect is roughly neutral for short-term policy economics and meaningfully positive for long-term policies that already span a dog's full lifetime. In other words, longevity drugs would not necessarily push premiums up, and might actually pull lifetime premiums down for owners on multi-year policies.

There's also an obvious commercial opportunity that several underwriters are openly discussing: bundling coverage for the longevity drug itself into mid-tier and premium policies as a differentiator. The current monthly cost of the leading investigational compounds, extrapolated to a likely launch price, would be in the same range as several existing common chronic medications — well within the actuarial tolerance of a standard policy structure.

The actuarial work also surfaces some uncomfortable scenarios. Polices with strict age-cutoff exclusions become much harder to defend if the underlying lifespan distribution shifts. Several underwriters are reviewing their age-cutoff terms in light of the modelling. Owners with policies that include hard age cutoffs should expect those terms to be revisited, possibly in either direction depending on the carrier.

For owners considering a new policy, the practical implication is that policy term length matters more than ever. A long-term policy locked in before any longevity drug is widely available is likely to be a structurally good deal if the drugs deliver on even a fraction of what the models assume. A short-term policy will be re-priced as soon as the actuarial picture clarifies, and most of the re-pricing risk runs in the owner's favour given current model outputs.

We'll publish a comparison of insurance carrier responses to the modelling work as more carriers go on the record over the next two quarters.